Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1276P - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Jean-Baptiste Assié

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

J. Assié1, R. Corre2, M. Giaj Levra3, C.Y. Calvet4, V. Grumberg5, A. Gaudin5, B. Jouaneton6, F. Cotté5, C. Chouaid1

Author affiliations

  • 1 Pneumology, CH Intercommunal de Créteil, 94010 - Créteil/FR
  • 2 Pulmonology, Centre Hospitalier Intercommunal de Quimper, Quimper/FR
  • 3 Pulmonology, CHU Grenoble Alpes - Site Nord La Tronche, 38700 - La Tronche/FR
  • 4 Medical Oncology, Bristol-Myers Squibb, 92500 - Rueil-Malmaison/FR
  • 5 Heor, Bristol-Myers Squibb SARL, 92506 - Rueil-Malmaison/FR
  • 6 Biostatistics, HEVA, Lyon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1276P

Background

Nivolumab, an anti-PD-1 antibody, demonstrated superior overall survival (OS) in phase III trials in patients previously treated for aNSCLC. The objective of UNIVOC was to describe in real-world setting the long-term outcomes of patients treated with nivolumab, overall and in three specific populations: elderly (80+ years), brain metastases (BMs), renal impaired.

Methods

Based on French National hospitals database, we constituted a retrospective cohort of all aNSCLC patients who initiated nivolumab in 2015-16 and were followed until Dec-18. Information on patients’ baseline characteristics (demographics, comorbidities, treatment history) was retrieved, and time to treatment discontinuation (TTD) and OS were estimated with Kaplan-Meier method.

Results

The overall cohort included 10,452 patients. Median age was 64 years, including 514 elderly patients (4.9%). At baseline, 1800 patients (17.2%) had BMs and 479 patients (4.6%) had renal impairment. Compared to younger patients, elderly presented with similar comorbidities but lower rates of BMs (5.6% vs. 17.8%; p<000.1). Patients with BMs were younger (median age: 60 vs 65 yrs; p<000.1) more frequently women (37.3% vs.27.3%; p<0.0001) than patients with no BMs. Patients with renal impairment presented higher rates of comorbidities than patients without renal impairment. Median TTD with nivolumab was 2.8 months in the overall, elderly and renal impaired populations, and 2.3 months in patients with BMs. In the overall population, median OS was 11.7 months [95%CI: 11.3–12.2] and 3-year OS rate was 19.1% [18.1%–20.2%]. Median OS and 3-year OS rates were 11.7 months [11.3–12.1] and 16.5% [11.6%–23.4%]) in elderly patients, 9.9 months [9.0–10.9] and 21.7% [19.4%–24.2%] in patients with BMs and 10.1 months [8.7–12.0] and 15.9% [11.8%–21.4%] in patients with renal impairment, respectively.

Conclusions

This large nationwide cohort reported narrow estimates of 3-year OS rate reaching 19%, in consistency with nivolumab phase III trials. Despite lower median OS in patients with BMs and renal impairment, long-term OS within special populations remained comparable to the overall population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Bristol-Myers Squibb.

Funding

Bristol-Myers Squibb.

Disclosure

M. Giaj Levra: Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: MSD; Advisory/Consultancy: Roche; Advisory/Consultancy: Novartis. C.Y. Calvet, V. Grumberg, A-F. Gaudin, F-E. Cotté: Full/Part-time employment: Bristol-Myers Squibb. B. Jouaneton: Full/Part-time employment: HEVA. C. Chouaid: Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: MSD; Advisory/Consultancy: Pierre Fabre Oncology; Advisory/Consultancy: Lilly ; Advisory/Consultancy: Roche; Advisory/Consultancy: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.